Adverum Biotechnologies Inc (NASDAQ:ADVM) — Market Cap & Net Worth
Market Cap & Net Worth: Adverum Biotechnologies Inc (ADVM)
Adverum Biotechnologies Inc (NASDAQ:ADVM) has a market capitalization of $96.26 Million ($96.26 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19423 globally and #4454 in its home market, demonstrating a 3.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adverum Biotechnologies Inc's stock price $4.36 by its total outstanding shares 22077467 (22.08 Million). Also see ADVM total assets for a full breakdown of the balance sheet.
Adverum Biotechnologies Inc Market Cap History: 2015 to 2025
Adverum Biotechnologies Inc's market capitalization history from 2015 to 2025. Data shows change from $2.10 Billion to $96.26 Million (-25.41% CAGR). Also see ADVM cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Adverum Biotechnologies Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #549 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1871 of 3165 |
Weight: Adverum Biotechnologies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adverum Biotechnologies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adverum Biotechnologies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ADVM share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
103.10x
Adverum Biotechnologies Inc's market cap is 103.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.10 Billion | $2.32 Million | -$47.45 Million | 906.33x | N/A |
| 2016 | $640.25 Million | $1.46 Million | -$113.75 Million | 440.03x | N/A |
| 2017 | $772.71 Million | $1.85 Million | -$56.15 Million | 417.91x | N/A |
| 2018 | $695.44 Million | $1.61 Million | -$72.63 Million | 431.41x | N/A |
| 2019 | $2.54 Billion | $250.00K | -$64.49 Million | 10173.30x | N/A |
| 2020 | $2.39 Billion | $7.50 Million | -$117.51 Million | 319.09x | N/A |
| 2021 | $388.56 Million | $7.50 Million | -$145.54 Million | 51.81x | N/A |
| 2022 | $127.94 Million | $3.60 Million | -$154.54 Million | 35.54x | N/A |
| 2023 | $166.20 Million | $3.60 Million | -$122.12 Million | 46.17x | N/A |
| 2024 | $103.10 Million | $1.00 Million | -$130.93 Million | 103.10x | N/A |
Competitor Companies of ADVM by Market Capitalization
Companies near Adverum Biotechnologies Inc in the global market cap rankings as of September 18, 2026. Review Adverum Biotechnologies Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Adverum Biotechnologies Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Adverum Biotechnologies Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Adverum Biotechnologies Inc's market cap moved from $2.10 Billion to $ 96.26 Million, with a yearly change of -25.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $96.26 Million | -6.64% |
| 2024 | $103.10 Million | -37.96% |
| 2023 | $166.20 Million | +29.91% |
| 2022 | $127.94 Million | -67.07% |
| 2021 | $388.56 Million | -83.76% |
| 2020 | $2.39 Billion | -5.90% |
| 2019 | $2.54 Billion | +265.71% |
| 2018 | $695.44 Million | -10.00% |
| 2017 | $772.71 Million | +20.69% |
| 2016 | $640.25 Million | -69.54% |
| 2015 | $2.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Adverum Biotechnologies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $96.26 Million USD |
| MoneyControl | $96.26 Million USD |
| MarketWatch | $96.26 Million USD |
| marketcap.company | $96.26 Million USD |
| Reuters | $96.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more